anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: Antipsychotics are recommended for prevention of relapse in schizophrenia. It is unclear whether increased risk of relapse following antipsychotic discontinuation is predominantly associated with an absolute magnitude of dose reduction or rate of antipsychotic reduction. Establishing the responsible mechanism is important because prolonged withdrawal schedules have been suggested to reduce risk of relapse.
STUDY DESIGN: Individual patient data from antipsychotic discontinuation studies were obtained. We estimated the occupancy of receptors over time using half-lives and median effective dose ED50 values obtained from pharmacokinetic and receptor occupancy studies. Hazard ratios for relapse events were calculated using Cox proportional hazards models to assess the influence of formulation (oral, 1-monthly, and 3-monthly injections). The change in hazard ratio over time was estimated, and the effect of time-varying covariates was calculated, including rate of occupancy reduction and absolute receptor occupancy.
STUDY RESULTS: Five studies including 1388 participants with schizophrenia were identified (k = 2: oral, k = 2: 1-monthly injection, k = 1: 3-monthly injection). Withdrawal of long-acting injectable medication did not lead to a lower hazard ratio compared with withdrawal of oral medication, and this included the period immediately following randomization. Hazard ratios were not associated with the rate of decline of receptor occupancy; however, they were associated with reduced absolute occupancy in trials of long-acting injections (P = .038).
CONCLUSIONS: Antipsychotic discontinuation is associated with an increased risk of psychotic relapse, related to receptor occupancy. Although relapse does not appear to be related to the rate of discontinuation, gradual discontinuation strategies may allow for easier antipsychotic reinstatement in case of symptomatic worsening.
PURPOSE: This study aims to develop a novel prediction model and risk stratification system that could accurately predict progression-free survival (PFS) in patients with nasopharyngeal carcinoma (NPC).
METHODS: Herein, we included 106 individuals diagnosed with NPC, who underwent 18F-FDG PET/CT scanning before treatment. They were divided into training (n = 76) and validation (n = 30) sets. The prediction model was constructed based on multivariate Cox regression analysis results and its predictive performance was evaluated. Risk factor stratification was performed based on the nomogram scores of each case, and Kaplan-Meier curves were used to evaluate the model's discriminative ability for high- and low-risk groups.
RESULTS: Multivariate Cox regression analysis showed that N stage, M stage, SUVmax, MTV, HI, and SIRI were independent factors affecting the prognosis of patients with NPC. In the training set, the model considerably outperformed the TNM stage in predicting PFS (AUCs of 0.931 vs. 0.841, 0.892 vs. 0.785, and 0.892 vs. 0.804 at 1-3 years, respectively). The calibration plots showed good agreement between actual observations and model predictions. The DCA curves further justified the effectiveness of the model in clinical practice. Between high- and low-risk group, 3-year PFS rates were significantly different (high- vs. low-risk group: 62.8% vs. 9.8%, p < 0.001). Adjuvant chemotherapy was also effective for prolonging survival in high-risk patients (p = 0.009).
CONCLUSION: Herein, a novel prediction model was successfully developed and validated to improve the accuracy of prognostic prediction for patients with NPC, with the aim of facilitating personalized treatment.
The NOD-like receptor family protein 3 (NLRP3) inflammasome is a crucial complex for the host to establish inflammatory immune responses and plays vital roles in a series of disorders, including Alzheimer's disease and acute peritonitis. However, its regulatory mechanism remains largely unclear. Zinc finger antiviral protein (ZAP), also known as zinc finger CCCH-type antiviral protein 1 (ZC3HAV1), promotes viral RNA degradation and plays vital roles in host antiviral immune responses. However, the role of ZAP in inflammation, especially in NLRP3 activation, is unclear. Here, we show that ZAP interacts with NLRP3 and promotes NLRP3 oligomerization, thus facilitating NLRP3 inflammasome activation in peritoneal macrophages of C57BL/6 mice. The shorter isoform of ZAP (ZAPS) appears to play a greater role than the full-length isoform (ZAPL) in HEK293T cells. Congruously, Zap-deficient C57BL/6 mice may be less susceptible to alum-induced peritonitis and lipopolysaccharide-induced sepsis in vivo. Therefore, we propose that ZAP is a positive regulator of NLRP3 activation and a potential therapeutic target for NLRP3-related inflammatory disorders.
Piroxicam USP is a nonsteroidal anti-inflammatory drug, available as maroon and blue 10 mg capsules and maroon 20 mg capsules for oral administration. The chemical name is 4-hydroxyl-2-methyl-N-2pyridinyl-2H-1,2,-benzothiazine-3-carboxamide 1,1-dioxide. The molecular weight is 331.35. Its molecular formula is C15H13N3O4S, and it has the following chemical structure.

Piroxicam occurs as a white crystalline solid, insoluble in water and anhydrous ethanol. It is slightly soluble in 0.1N sodium hydroxide and soluble in methylene chloride. It exhibits a weakly acidic 4-hydroxy proton (pKa 5.1) and a weakly basic pyridyl nitrogen (pKa 1.8).

The inactive ingredients in piroxicam capsules USP include: lactose monohydrate, corn starch, sodium lauryl sulfate, magnesium stearate, gelatin, FD&C Blue 1, D&C Red 33, FD&C Red 40, D&C Red 28, titanium dioxide and trace amount of white edible ink.
The invention discloses a no-wash hair cleaning and caring composition, and relates to the technical field of hair washing and caring. The leave-on hair cleansing care composition comprises a substrate a and a liquid composition B. The penetration ratio of the liquid composition B in the non-woven fabric base material A is 2:1-5:1, and the viscosity of the liquid composition B is extremely low, so that the liquid composition B can uniformly penetrate in the base material A. The liquid composition B comprises, by weight, 4-10 parts of amino silicone oil emulsion, 1-5 parts of water-soluble grease and 2-6 parts of a solubilizer. The base material A and the liquid composition B are matched for use, so that the hair cleaning liquid can play a role in cleaning hair dirt, meanwhile, the wiping process is equivalent to the process of uniformly coating components on the whole hair, and the hair has good softness and soft touch feeling from the wet state to the dry state. The no-wash hair cleaning and nursing composition is convenient to carry, is suitable for various emergency occasions, does not need to be washed with water after being used, and is fresh, cool, not greasy, smooth, not frizzy and moist and glossy.
PURPOSE: To obtain the subject plaster containing dexpanthenol as an infiltrative auxiliary agent, raised in the dermal infiltrativity of an active substance, and suppressed or mitigated in the skin-irritating effect of the active substance and an adjuvant. CONSTITUTION: This plaster contains an active substance <1,000 in molecular weight useful for the systemic system, Carlen type adjuvant of common use (e.g. an adhesive as a polymer with a glass transition temperature of -70 to -100esp. -55 to -25 deg.C), and dexpanthenol as an infiltrative auxiliary agent. The matrix of this plaster is prepared by the following process: the active substance and dexpanthenol are dissolved or finely dispersed in an appropriate polymer solution to afford a self-adhesive compound, which, in turn, made into a filmy form by roll coating or knife coating process. The active substance mentioned above is e.g. an opium agent, calcium antagonistic agent, hypotensive, antiarrhythmic agent, β-receptor blocker, psycholeptic agent, vasodilator, antihistaminic agent, antirheumatic agent, hormone preparation.
BACKGROUND AND AIMS: Low-grade squamous intraepithelial lesion (LSIL) is one of two categories of cervical intraepithelial lesions. Given that controversy exists regarding its management, this comparative study aimed to evaluate the effect of 5-aminolevulinic acid photodynamic therapy (ALA-PDT) in treating LSIL of the high-risk human papillomavirus (HR-HPV)-infected cervix.
METHODS: A total of 218 patients (25-45 years old) with cervical LSIL associated with HR-HPV who underwent ALA-PDT, loop electrosurgical excision procedure (LEEP), or observation only were included. The clearance rates of cervical LSIL and HR-HPV between the ALA-PDT, LEEP, and observation groups were compared at 6 and 12 months follow-up. Adverse reactions were also compared. The factors affecting the clearance on ALA-PDT of cervical LSIL were evaluated.
RESULTS: There were no statistically significant differences in lesion and HR-HPV clearance rates between the ALA-PDT and LEEP groups at 6 and 12 months. However, the lesion and HR-HPV clearance rates were significantly higher in the ALA-PDT group than that in the observation group. The adverse reaction rate was significantly lower in the ALA-PDT group than in the LEEP group.
CONCLUSION: For patients with cervical LSIL, the lesion and HR-HPV clearance rates after ALA-PDT were close to those after LEEP and significantly higher than in the observation group. Moreover, the adverse reaction rate for ALA-PDT was much lower than that for LEEP. Therefore, ALA-PDT provides a new option for the minimally invasive treatment of cervical LSIL.
The invention discloses a stemona tincture agent for treating pruritus cutanea, for treating pruritus cutanea, the conventional western medicines are an antihistamine drug, a calcium agent and hormone. The western medicines have many taboo, and frequently cause drowsiness, hypodynamia and other side effects, which can influence the normal life and work of the patients, and the patients with chronic disease are difficult for adherence treatment. The stemona tincture agent is composed of 1-3 parts of roots of oriental buckthorn and 1-3 parts of radix stemonae. A preparation method comprises the following steps: taking the clean and dry raw materials, crushing to coarse grain, immersing in 10-30 parts of alcohol with 75% (V/V) of concentration, immersing for 7-15 days, taking out and filtering, and packaging a filtrate to obtain the stemona tincture agent. The stemona tincture agent for treating pruritus cutanea has the efficacy of clearing heat and detoxifying, killing insects and disinhibiting dampness, and relieving itching, and can be used for pruritus cutanea due to pathogenic wind and damp evil. Through clinical verification, the stemona tincture agent is sprayed on the affected part, 133 cases of pruritus cutanea can be treated, good clinical curative effect can be achieved, the effective rate can reach 96.3%, local anaphylaxis and anaphylaxis for whole body are not discovered during a medication period, and the medication is safe.
Not for prolonged use. If redness, pain, irritation or swelling persists, discontinue use and consult a physician. Contents of the container are under pressure. Do not burn or puncture the aerosol container. Do not store at temperatures above 120°F (49°C). Keep this and all medicines out of the reach of children.
RA begins data collection with chart review for demographic and explanatory variables, collects data for baseline muscle strength. During standard care period, PM will obtain information about the plan for activity for enrolled patients (turning, complete or partial weight-bearing i.e., reverse Trendelenberg positioning, ROM, sitting and walking) through discussion with the direct providers. RA will interview one provider about factors which influence the decision to implement activity or provide bedrest, including the presence of orders for bedrest or physical therapy. If activity is planned, the PM will observe and record the type and duration of activity, drawing serum biomarkers 20 minutes before and 20 minutes after the activity. If no activity is planned or activity duration is less than 10 minutes, serum for only baseline inflammatory biomarkers will be drawn. The RA will collect outcomes data within 24 hours of discharge from the ICU.
Patients in both the Solid Tumor Cohort and the CNS Cohort will receive cemiplimab monotherapy. Each Cohort will have 2 subgroups by age (0 to \<12 years, 12 to \<18 years).
PROBLEM TO BE SOLVED: To obtain a mature type protein having antagonistic actions on a bone morphogenetic protein. SOLUTION: This mature type protein having an antagonistic activity for a bone morphogenetic protein is obtained by converting at least one residue in methionine residue or tryptophan residue present in an amino acid sequence of a mature type human MP52 into a hydrophilic group according to a chemical modification or substituting the residue with a hydrophilic amino acid residue or a polar amino acid residue. The chemical modification of the methionine residue is carried out by an oxidation or an alkylation. The chemical modification of the tryptophan residue is conducted by an arylsulfenylation. The resultant mature type protein is useful as a therapeutic agent or a prophylactic agent for metabolic diseases accompanying heterotropic ossification or calcification. Furthermore, the mature type protein is useful as a reagent for screening a drug competitive with the bonding of the bone morphogenetic protein to a receptor thereof or in an evaluation system.
General symptomatic and supportive measures should be used along with immediate gastric lavage where appropriate. Intravenous fluids should be administered as needed. Animal studies suggest that flumazenil is an antagonist to zaleplon. However, there is no pre-marketing clinical experience with the use of flumazenil as an antidote to a Zaleplon overdose. As in all cases of drug overdose, respiration, pulse, blood pressure, and other appropriate signs should be monitored and general supportive measures employed. Hypotension and CNS depression should be monitored and treated by appropriate medical intervention.
Genetically engineered T-cells including a polynucleotide encoding a negative selective marker are used in the manufacture of a medicament for a) preventing graft-versus-host disease in a host being treated for relapsed or persistent leukemia or b) treating a disease or disorder in a host wherein the treatment of the disease in the host includes ablating the bone marrow of the host and administering to the host a T-cell depleted bone marrow transplant. An interaction agent is used in the manufacture of a medicament for c) preventing graft-versus-host disease in a host being treated for relapsed or persistent leukemia or d) treating a disease or disorder in a host wherein the treatment of the disease in the host includes ablating the bone marrow of the host and administering to the host a T-cell depleted bone marrow transplant. The uses defined above involve administering an effective amount of the interaction agent to the host, prior to the occurrence of graft-versus-host disease, to kill T-cells capable of providing a graft-versus-host effect in the host through the interaction of the interaction agent with the negative selective marker. An expression vehicle comprising a polynucleotide encoding a negative selective marker is used in the manufacture of a medicament for preventing graft-versus-host disease in a host being treated for relapsed or persistent leukemia. The use of the expression vehicle defined above involves administering an effective amount of the interaction agent to the host, prior to the occurrence of graft-versus-host disease, to kill T-cells: e) that have been transduced with the expression vehicle and f) which are capable of providing a graft-versus-host effect in the host through the interaction of the interaction agent with the negative selective marker. The negative selective marker can be herpes simplex virus thymidine kinase, cytomegalovirus thymidine kinase or varicella zoster virus thymidine kinase.
The waitlist control group participants do not have access to the Daylight program during the study, which lasts from pregnancy to 8-weeks after delivery. However, they will be given access to Daylight after completing the 10-week follow-up survey.
In the experimental group, patients will benefit from a 20-minute VR. Patients will watch a forest walk in virtual reality while listening to narrations designed to induce relaxation and meditation. If the oocyte retrieval was not completed within 20 minutes, patients will watch the same VR program again.The TCI remifentanil and propofol will be connected to the infusion but will be stopped and titrated if discomfort.
This invention provides for a composition capable of inhibiting specific binding between a signal-transducing protein and a cytoplasmic protein. This invention also provides a method of identifying a compound capable of inhibiting specific binding between a signal-transducing protein and a cytoplasmic protein. This invention also provides a method of inhibiting the proliferation of cancer cells. This invention also provides a method of treating cancer with a composition in an amount effective to result in an amount in apoptosis of the cells. This invention also provides a method of inhibiting the proliferation of virally infected cells. This invention also provides for a method of treating a virally-infected subject with a composition in an amount effective to result in apoptosis of the cells. This invention also provides for pharmaceutical compositions.
BACKGROUND: Metabolic dysfunction-associated steatotic liver disease (MASLD) contributes to cardiovascular events. Therefore, we aimed to identify the association of MASLD, as indicated by the fatty liver index (FLI), on sudden cardiac arrest (SCA) in young adults.
METHODS: We analyzed data from adults aged 20-39 years, who underwent health examinations between 2009 and 2012, sourced from the Korean National Health Insurance Service database. The presence of MASLD was determined using the FLI, which was calculated based on an individual's body mass index, waist circumference, gamma-glutamyl transferase and triglyceride levels. The primary outcome was the occurrence of SCA during the follow-up period, until December 2020.
RESULTS: Of the total 5,398,082 individuals analyzed, 4,021,056 (74.5 %) had a normal FLI (FLI <30), 837,943 (15.5 %) were within the intermediate range (30-60), and 539,083 (10.0 %) demonstrated a high FLI (≥60). Individuals with a high FLI were older, and comprised a higher proportion of men with hypertension, diabetes mellitus, dyslipidemia, heart failure, and myocardial infarction. During follow-up, SCA occurred in 4255 individuals (0.08 %). The group with a high FLI exhibited an increased incidence (incidence rate, 0.19) and elevated risk of SCA (hazard ratio, 3.04). Adjustment of covariates revealed a 55 % increased risk of SCA in the high FLI group (adjusted hazard ratio 1.55, 95 % confidence interval 1.41-1.70, p < 0.001). Moreover, the influence of a high FLI on SCA risk was more pronounced in women compared to men. Additionally, an increase in relevant cardiometabolic conditions was associated with an elevated risk of SCA.
CONCLUSIONS: Among young adults, a high risk of MASLD, as indicated by the FLI, revealed an increased risk of SCA. Furthermore, the association of FLI with the risk of SCA varied by sex and cardiometabolic conditions.
The regimen-related toxicities associated with bone marrow transplantation (BMT) can be severe and even life threatening. The overall goal of this randomized controlled pilot study in BMT patients is to determine the effect of relaxation/stress reduction strategies on: (1) the frequency/severity of toxic side effects of marrow ablative chemotherapy, and (2) the timing of immune reconstitution. Substantial literature indicates that music therapy-based interventions are effective in inducing relaxation and also affect immune function by modulating circulating and salivary levels of such agents as cortisol, immunoglobulin A, interleukin-1, natural killer cells, and a variety of other immune system-related substances. Over the past two years, we have provided music therapy-based stress reduction/relaxation interventions to a convenience sample of patients undergoing BMT. Preliminary findings from this pilot feasibility study demonstrate that patients report significantly decreased pain (p\< .004) and sense of nausea (p \< .001) following an intervention. Average time-to-engraftment was 13.5 (+/- 2.85) days as compared to 15.5 (+/- 4.40) days (p \< .O1) for a group of historical controls matched on diagnosis, type of transplant, conditioning regimen, date of transplant, age, and gender. Although highly promising, our data are limited by lack of randomization, an appropriate control condition, measurement of psychologic factors known to influence outcome in BMT, and systematic monitoring of early phase markers of immune reconstitution that could help explain the phenomena we have observed. This proposal corrects these shortcomings and especially highlights the potential mediational effect of cytokine release on regimen-related toxicities and the timing of immune reconstitution.
Subjects in the prospective control group will receive standard tacrolimus dosing as recommended per package insert and will not be dosed based on their genotype. Similarly, subjects that underwent renal transplant after 2010 and received standard tacrolimus dosing (per package insert) will serve as historical controls.
Nesfatin concentrations are positively correlated with beta cell function. However, it is unclear whether diet composition mediates this relationship. We recruited 27 overweight individuals who practiced Orthodox fasting (OF), a subset of the Mediterranean diet (MedDiet), for 7 weeks. Fourteen overweight people who practiced 16:8 time-restricted eating served as control group. Anthropometric parameters, biochemical data and adipokine levels were evaluated at baseline and after the end of the diet period (7 weeks from baseline). Subsequently, participants were asked to return to their usual eating plans, and an additional evaluation was performed 5 weeks after the end of the research diets (12 weeks from baseline). We observed a significant and negative correlation between HOMA-B and nesfatin values at 12 weeks, only in the OF group (r = -0.455, p = 0.01). In conclusion, returning to normal eating habits after 7 weeks of strict adherence to MedDiet affects the homeostatic balance between insulin secretion and nesfatin.
PROBLEM TO BE SOLVED: To obtain an anti-herpes virus agent having an anti-herpes virus activity remarkably superior to heparin and dextran sulfate and useful for the prevention, maintenance, amelioration and cure of herpes virus-relating diseases by using a specific sulfated polysaccharide as an active component. SOLUTION: This agent contains a sulfated polysaccharide containing a disaccharide unit having a glycoside bond bonding the 1-site of a uronic acid residue and the 3-site of a hexosamine residue and sulfated at the 4-site and the 6-site of the hexosamine residue. The sulfated polysaccharide is especially preferably composed of a repetition of disaccharide units each containing a glycoside bond bonding the 1-site of the uronic acid residue and the 3-site of the hexosamine residue. The uronic acid residue is preferably glucuronic acid residue, etc., and the hexosamine residue is preferably galactosamine residue. The sulfated polysaccharide preferably has a ΔDi-diSE content of 30-100% by disaccharide analysis and a molecular weight of 5,000-150,000. The active component of the agent is especially preferably chondroitin sulfate E, etc.